-transparent.png){kind=logo}
A series of novel pazopanib derivatives, 7a-m, were designed and synthesized by modification of terminal benzene and indazole rings in pazopanib. The structures of all the synthesized compounds were confirmed by (1)H NMR and MS. Their inhibitory activity against VEGFR-2, PDGFR-α and c-kit tyrosine kinases were evaluated. All the compounds exhibited definite kinase inhibition, in which compound 7l was most potent with IC50 values of 12 nM against VEGFR-2. Furthermore, compounds 7c, 7d and 7m demonstrated comparable inhibitory activity against three tyrosine kinases to pazopanib, and compound 7f showed superior inhibitory effects than that of pazopanib.
Related Publications
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
March 2014,
Chemical biology & drug design,
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
March 2011,
Molecules (Basel, Switzerland),
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
November 2013,
Bioorganic & medicinal chemistry,
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
May 2013,
Archives of pharmacal research,
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
August 2019,
European journal of medicinal chemistry,
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
November 2011,
Archiv der Pharmazie,
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
June 2014,
Drug discoveries & therapeutics,
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
May 2024,
Bioorganic chemistry,
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
January 2019,
Frontiers in chemistry,
Haofei Qi, and
Ligong Chen, and
Bingni Liu, and
Xinran Wang, and
Li Long, and
Dengke Liu
September 2018,
Molecules (Basel, Switzerland),
